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Abstract 
It has been recently proposed that the two “emerging” hallmarks of cancer, namely 
altered glucose metabolism and immune evasion, may in fact be fundamentally linked 
(1). This connection comes from up-regulation of glycolysis by tumor cells, which can 
lead to active competition for resources in the tumor microenvironment between tumor 
and immune cells. Here it is further proposed that cancer stem cells (CSCs) can 
circumvent the anti-tumor immune response by creating a ‘protective shield’ of non-stem 
cancer cells around them. This shield can protect the CSCs both by creating a physical 
barrier between them and cytotoxic lymphocytes (CTLs), and by promoting competition 
for the common resources, such as glucose, between non-stem cancer cells and CTLs. 
The implications of this hypothesis are investigate  using an agent-based model, leading 
to a prediction that  relative CSC to non-CSC ratio will vary with the strength of the host 
immune response, with the highest occurring at an intermediate state of immune 
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activation. A discussion of possible therapeutic approaches concludes the paper, 
suggesting that a chemotherapeutic regimen consisting of regular pulsed doses, i.e., 
metronomic chemotherapy, would yield the best clinical outcome by allowing CTLs to 
most effectively reach and eliminate CSCs. 
 
Introduction 
The immune system is generally very effective in preventing budding tumors from 
progressing to a fully malignant disease (2-4).  However, as the cytotoxic cells of the 
immune system attempt to eliminate the tumor, they effectively select for non-
immunogenic clones, thus delaying but not arresting tumor progression, a process that 
has become known as tumor immunoediting (2; 5-7). Moreover, tumors that have been 
‘edited’ in this fashion are typically more aggressive than their ‘unedited’ counterparts 
due to selection for more immunoresistant clones; a property first demonstrated by 
Shankaran and colleagues (8).  
It has been recently proposed that the process of immunoediting may additionally be 
driven by competition for resources between cancer and immune cells in the tumor 
microenvironment  (1). Specifically, the following microenvironmentally-based 
immunoediting scenario has been proposed: 
1) As the tumor increases in size while not yet recognized by the cytotoxic cells of 
the immune system, it begins to outgrow its blood supply, causing the formation 
of oxygen-deprived regions in the tumor interior. 
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2) Intra-tumoral hypoxia causes the affected tumor cells to turn to glycolysis as a 
primary mode of glucose metabolism; an event known to be accompanied by an 
up to 30-fold up-regulation of the activity of glucose transporters (9). 
3) Once activated, the CTLs first attack the topologically accessible outer rim of the 
tumor, what we term the ‘protective shield’, thus effectively exposing the tumor’s 
‘glycolytic core’. 
4) The exposed glycolytic tumor cells, which have been forced to up-regulate their 
glucose transporters, now actively compete with CTLs for glucose. 
5) In a nutrient-deprived state, CTLs are less able to perform their tumoricidal 
function, allowing the tumor as a whole to evade immune attack. 
In this way, the process of immune evasion may be the result of a competition for 
resources in the tumor microenvironment. 
Here, this construct is expanded to incorporate cancer stem cells (CSCs).  Because 
CSCs comprise a relatively small fraction of the tumor population on account of their 
high probability of asymmetric division (producing one CSC and one non-stem cell) (10), 
they will tend to surround themselves with non-stem progeny, which then could follow 
the aforementioned immunoediting scenario . The non-CSCs will then protect CSCs from 
cytotoxic lymphocytes both by creating a physical barrier and through outcompeting 
CTLs for essential nutrients.  These considerations are summarized in Figure 1. 
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Figure 1. Schematic representation of the proposed immunoediting construct, which 
incorporates CSCs using aerobic and particularly glycolytic non-CSCs as a protective 
‘shield’ from cytotoxic lymphocytes. 
 
The proposed theoretical framework allows making predictions about CSC 
content in different tumors with regards to the immune response, which can be of vital 
importance, as CSCs, the driving cells in cancer progression, are believed to be more 
resistant to cytotoxic therapy than non-CSCs (11-14). In this case, if CSCs produced too 
few non-CSCs, protection from the immune system could be insufficient. If CSCs 
produced too many non-CSCs, then the progeny may themselves become limiting to CSC 
expansion, offsetting their benefit as an immune shield. Successful tumors might 
therefore be predicted to be those that have some optimal intermediate CSC-to-progeny 
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proportion. In addition, this proportion may well be different for different initial states of 
the immune system. 
To test these ideas, an agent-based model is implemented, incorporating the 
foregoing and other basic assumptions about the properties of CSCs, non-CSCs, immune 
cells and their interactions with each other and with the resources in the tumor 
microenvironment. We use this model to illustrate the proposed immunoediting construct 
and in particular, to evaluate the proposition that varying proportions of CSCs to non-
CSCs might be expected in successful tumors under different immune conditions. 
Model description 
Here we build upon a previously introduced agent-based model (15), adapting it to 
describe the interactions between cancer stem cells (CSCs), aerobic and glycolytic non-
stem cancer cells (non-CSCs), and cytotoxic lymphocytes (CTLs) with each other and 
their microenvironment. The model is implemented in Netlogo 5.0.2, a freely available 
agent-based modeling platform (16). Space in this simulation is represented by a 2-
dimensional 51x51 lattice. Each patch (square) in the lattice represents a discrete 
microenvironment, the properties of which are detailed below, for a total of 2601 
microenvironments. Cells occupy coordinates in continuous space, and more than one 
cell can occupy a single microenvironment. Time is modeled in discrete steps. 
Parameter estimation 
Parameter estimation is a common challenge in analyzing results from 
computational models. One particular difficulty lies in the fact that the estimates 
obtained in an experimental setting are typically a result of a multitude of complex 
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interconnected processes, which cannot always be separated out for the purposes of 
a conceptual proof-of-concept model. We address this issue in the following ways. A 
number of parameters, such as cell growth rates, were previously estimated in a 
model introduced and analyzed in (15), where the authors utilize an agent-based 
model to evaluate the impacts of disregulated glucose metabolism on overall tumor 
dynamics. We modify their proposed model, shifting the focus of our investigation 
away from evolution of cell motility and instead introducing immune cells and 
cancer stem cells as active competitors for glucose in the tumor microenvironment. 
Nevertheless, parameters that pertain to tumor growth rates and glucose 
consumption rates can be well translated into our model. 
For a number of other parameters, while it may not always be possible to 
obtain exact values for reasons outlined above, we attempt to make estimations 
based on the parameters’ relative values to each other. That is, while we may not be 
able to estimate exact rates of glucose consumption by cytotoxic immune cells, for 
instance, we can nevertheless support the notion that highly proliferative CTLs, just 
as glycolytic tumor cells, consume more energy than do aerobic tumor cells (17). 
Morover, Buttgereit and Brand (18) reported that in a model of concanavlin A-
stimulated thymocytes, where it is possible to account for over 80% of ATP 
consumption, protein synthesis was the most sensitive to limitations in glucose 
supply, followed by DNA and RNA synthesis and then by ion transport across 
plasma membrane. Motility also has been reported to incur significant ATP costs for 
immune cells due to energy requirements for cytoskeleton rearrangement during 
movement (19). Therefore, while we may not be able to obtain the exact values for 
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the costs of motility and cytotoxicity for CTLs, we can nevertheless assert that these 
costs exist, and are incorporated as such. Moreover, since we do not have exact 
estimates for these costs, they are taken to be a unit of energy each, an assumption 
which can be relaxed or modified pending data availability. 
The specific assumptions for each of the cell types and for the microenvironments 
are as follows: 
Properties of aerobic non-CSCs: Aerobic non-CSCs require glucose and oxygen for 
survival and glucose for proliferation, although they have lower glucose requirements 
than glycolytic non-CSCs. They die at some natural rate, as well as after a certain number 
of divisions, and can also be killed by CTLs. They can ‘switch’ to the glycolytic mode of 
metabolism under conditions of oxygen deprivation.  When a cell divides, the daughter 
cell moves to a random neighboring patch. 
Properties of glycolytic non-CSCs: Glycolytic non-CSCs do not require oxygen, but 
require glucose for survival and proliferation; they consume more glucose to support 
these processes than aerobic non-CSCs. They die at some natural rate, as well as after a 
certain number of divisions, and can also be killed by CTLs.  They can ‘switch’ to the 
aerobic mode of glucose metabolism under conditions of sufficient oxygen availability. 
When a cell divides, the daughter cell moves to a random neighboring patch. 
Properties of cancer stem cells: Depending on oxygen availability, CSCs consume 
oxygen and glucose like aerobic or glycolytic cells. Each CSC division occurs 
symmetrically with a certain probability. If a CSC divides asymmetrically, the daughter 
non-CSC cell is initialized to be aerobic, a state which may change. Each cell can die due 
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to nutrient deprivation or be killed by CTLs. CSCs can divide an unlimited number of 
times. When a CSC divides, the daughter cell moves to a random neighboring patch. 
Properties of cytotoxic immune cells: It is assumed that all cytotoxic CTLs rely on 
glycolysis for glucose metabolism, consuming nutrients at the same rate as glycolytic 
tumor cells. CTLs can proliferate only under conditions of sufficient glucose supply. 
They can die from nutrient deprivation.  Unlike tumor cells, CTLs are motile and move 
randomly throughout the microenvironment. As motility is costly, each step to a random 
neighboring patch costs CTLs a unit of energy. CTLs can kill tumor cells once they 
encounter them; however, killing a tumor cell also costs a unit of energy. CTLs are 
replenished at some constant rate when the number of immune cells in the tumor 
microenvironment becomes too low. 
Properties of the microenvironment: On each patch there is a certain amount of 
glucose and oxygen. Both glucose and oxygen are replenished differentially, depending 
on the number of cells on the patch. Too many cells on the patch lowers the rate of 
replenishment, which simulates the crowding effect. Glucose and oxygen are taken up by 
different cell types at different rates, depending on whether the cell type is aerobic, 
glycolytic, stem or immune. 
It is worth noting that while alternative energy sources, such as glutamine, are 
available to tumor cells, it has been shown by MacIver and colleagues (20) that activated 
T cells are unable to perform their function in the absence of glucose, even in the 
presence of amply available glutamine. Therefore, glutamine was not incorporated as an 
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energy source in the proposed model as it is not the driving force for competition 
between tumor and immune cells.  
The model is initialized with a single CSC and a pre-set initial number of 
cytotoxic immune cells placed randomly throughout the lattice. At each time step, the 
following sequence of steps is realized: 
1) Each tumor cell evaluates oxygen availability in its microenvironment, which 
determines the cell’s subsequent mode of glucose metabolism. 
2) Each cell consumes glucose, subtracting differentially from the glucose 
available on the patch and adding a number of energy units to the cell’s 
storage, according to its ‘metabolic phenotype’, i.e., aerobic or glycolytic; 
glycolytic cells consume glucose, while aerobic cells consume both glucose 
and oxygen. 
3) Cytotoxic lymphocytes move randomly throughout the microenvironment, 
killing the tumor cells that they encounter; both motility and the process of 
cell killing have a cost of a unit of energy each; CTLs die if their energy stores 
are depleted and cannot be replenished. 
4) Each cell reproduces with a certain fixed probability, given adequate 
resources in the microenvironment; the daughter cell moves to a random 
neighboring patch; if the cell is a CSC, it divides symmetrically or 
asymmetrically with a certain probability; in case of asymmetric division, the 
daughter cell is initialized as aerobic non-CSC. 
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5) Glucose and oxygen are replenished in the microenvironment depending on 
the number of cells on each patch, with a higher rate of replenishment in the 
areas of lower cell density. 
6) CTLs are replenished by the value of parameter i0 if the number of immune 
cells on the lattice falls below a critical threshold. 
Since the purpose of the proposed model is to offer a ‘proof-of-concept’ as to whether 
tumor composition can indeed be affected by the initial state of the immune system of the 
host, parameter values were chosen as relative to each other rather than matching them to 
fit a particular data set. 
It is hypothesized that in successfully formed tumors, the relative proportion of 
non-CSCs will increase proportionally to the strength of the immune response because 
CSCs will require the shielding effect of non-CSCs to protect them from CTLs. 
Specifically, an increase in the proportion of glycolytic non-CSCs is predicted, since they 
are capable of competing most effectively with CTLs for glucose in the tumor 
microenvironment. 
Results  
The numerical experiments were designed in such a way as to enable evaluation of tumor 
composition at each time point with respect to the state of the immune system. The initial 
state of the immune response was modeled with parameter i0=0, 10, 20, 30, 35, 40. For 
each i0, 20 simulations were run for 1000 time steps, and the mean number of CSCs, 
aerobic and glycolytic non-CSCs were reported; only the data for tumors that had at least 
one CSC at t=1000 were collected. The data is represented in two types of plots: the 
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change over time of tumor composition for each respective i0 and the final ratio of CSC 
to non-CSC at t=1000 for each i0.  
Proportion of glycolytic cells increases with the strength of the immune response 
Our simulations show that indeed, stronger immune response predicts larger overall 
proportion of glycolytic non-CSCs in the tumor (see Figure 2), which within the proposed 
theoretical framework is explained by the increased ‘need’ of CSCs to protect themselves 
from the immune system. However, the largest proportion of CSCs in the tumor at 
t=1000 was observed at the intermediate values of i0 (see Figure 3).  
 
Figure 2. Change in tumor composition of CSCs (green) to glycolytic nCSCs (red) to 
aerobic nCSCs (blue) over time for varying initial states of the host immune system, 
represented by parameter i0. As one can see, the proportion of glycolytic nCSCs 
tends to increase with i0 as CSCs require increased protection from CTLs. Threshold 
of sensitivity to oxygen for all cells is set to ω=5. 
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Figure 3. Proportion of CSCs and nCSCs at t=1000 for all varying initial states of the 
host immune system, represented by parameter i0. As one can see, the highest 
proportion of CSCs is observed not for immunodeficient or extremely 
immunocompetent host, but for intermediate values of i0. Threshold of sensitivity to 
oxygen for all cells is set to ω=5. 
 
The following explanation for this phenomenon is proposed:  
At low values of i0, aerobic non-CSCs that are located on the tumor rim have the greatest 
competitive advantage compared to other tumor cells, as they have the most access to 
oxygen and glucose compared to both CSCs and glycolytic non-CSCs inside the tumor. 
Therefore, since they are not ‘sacrificed’ to the immune system, aerobic non-CSCs 
outcompete CSCs.  
At high values of i0, the tumor is not able to grow to a large enough size to create 
sufficiently hypoxic regions that would allow for the appearance of large clusters of 
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glycolytic non-CSCs that would present sufficient competition to cytotoxic lymphocytes. 
In this case, the non-CSC ‘shield’ would not be strong enough to contain CTLs.  
At “intermediate” values of i0, the tumor can grow to be large enough in size to have 
sufficiently large hypoxic regions to require up-regulation of purely glycolytic mode of 
glucose metabolism in a sufficiently large number of non-CSCs, while the immune 
system removes enough of the aerobic non-CSCs at the outer rim of the tumor to prevent 
them from outcompeting the rest of the tumor cells.    
Therefore, one should expect the largest proportions of CSC in hosts with “intermediate” 
states of immune system. (Noticeably, these observations can be made based on 
assumptions of relative values of parameters, without requiring exact parameter 
estimation from specific data sets). 
It has been reported by some groups that CSCs may have lower immunogenicity 
compared to non-CSCs (21,22). Intriguingly, while the same pattern of results was 
observed for various modifications in parameter values for costs of CTL motility and 
cytotoxicity (data not reported), differences were observed when the probability of 
recognition of CSCs by CTLs was decreased by 50% (Figures 4 and 5); this value was 
chosen arbitrarily due to lack of specific data. It appears that the proportion of CSCs 
varies with respect to the values of i0 only if CSCs are as likely to be killed by CTLs 
upon encounter as are non-CSCs. Otherwise, proportion of CSC:non-CSC remains the 
same regardless of the strength of the immune response. 
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Figure 4. Change in tumor composition of CSCs (green) to glycolytic nCSCs (red) to 
aerobic nCSCs (blue) over time for varying initial states of the host immune system, 
represented by parameter i0. The probability of recognition of CSC by a CTL is 50% 
lower than probability of recognition of nCSC. Threshold of sensitivity to oxygen for 
all cells is set to ω=5. 
 
Figure 5. Proportion of CSCs and nCSCs at t=1000 for all varying initial states of the 
host immune system, represented by parameter i0. The probability of recognition of 
CSC by a CTL is 50% lower than probability of recognition of nCSC. Threshold of 
sensitivity to oxygen for all cells is set to ω=5. 
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Variability in sensitivity to oxygen does not affect final tumor composition 
regardless of the state of the immune system 
In the previous set of in silico experiments, it was assumed that all cells have a fixed 
threshold of sensitivity to oxygen and therefore revert to either aerobic or glycolytic 
mode of glucose metabolism based on a criterion that is uniform for all cells. It is 
however possible that if there were heterogeneity among cells based on this metric, one 
could observe selection for cells that are either more or less sensitive to oxygen 
concentrations in their microenvironment depending on the state of the immune response. 
That is, one could observe selection towards lower oxygen sensitivity thresholds 
(described by the value of parameter ω) under the conditions of increased selective 
pressure from the immune system. 
In order to evaluate this hypothesis, the above-described protocol was modified to 
introduce mutations in parameter ω every time a tumor cell divides. The changes in the 
mean value of ω were recorded for all three cell types for all i0. The overall tumor 
composition changed in the same way with respect to different i0 as it did for the case of 
constant ω (Figure 6), and the largest proportion of CSCs was also observed for the 
intermediate values of i0 (Figure 7). The mean value ω for glycolytic cancer cells did 
oscillate increasingly with stronger immune response (Figure 8). However, a 2-tailed type 
1 t-test did not reveal any statistically significant changes either in overall tumor 
composition or in the values of ω at t=1000 for either of the three tumor cell types 
(Figure 9), These results suggest that it is not oxygen availability but competition for 
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glucose, both within the tumor and between cancer and immune cells, that is the driving 
force behind the observed dynamics of immune evasion. 
 
Figure 6. Change in tumor composition of CSCs (green) to glycolytic nCSCs (red) to 
aerobic nCSCs (blue) over time for varying initial states of the host immune system, 
represented by parameter i0. As one can see, the proportion of glycolytic nCSCs 
tends to increase with i0 as CSCs require increased protection from CTLs. Threshold 
of sensitivity to oxygen for all cells is initiated at ω=5 but is allowed to mutate with 
each cell division for each cell. 
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Figure 7. Proportion of CSCs and nCSCs at t=1000 for all varying initial states of the 
host immune system, represented by parameter i0. As one can see, the highest 
proportion of CSCs is observed not for immunodeficient or extremely 
immunocompetent host, but for intermediate values of i0. Threshold of sensitivity to 
oxygen for all cells is initiated at ω=5 but is allowed to mutate with each cell division 
for each cell. 
 
Figure 8. Change in the mutating threshold of sensitivity to oxygen (parameter ω) 
over time for varying initial states of the host immune system, represented by 
parameter i0. As one can see, while ω oscillates increasingly for larger i0, the mean of 
ω remains largely the same for all three cell types.  
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Figure 9. Mean value of the threshold of sensitivity to oxygen (parameter ω) at 
t=1000 for varying initial states of the host immune system, represented by 
parameter i0, compared to fixed value of ω=5 for the first set of simulations. While 
there are slight changes in ω for all three cell types, none of them were statistically 
significant as evaluated by a 2-tailed type 1 t-test, suggesting that it is not oxygen 
availability. 
 
Discussion 
Here a theoretical framework is proposed, where CSCs can escape recognition by 
cytotoxic lymphocytes by creating a ‘shield’ of differentiated non-CSCs around them. 
These shielding cells not only provide a physical barrier to the immune cells but also 
create a local nutrient flux, thereby starving CTLs out of functionality. Specifically, we 
proposed that if a CSC divided asymmetrically before it was recognized by the CTLs, 
and if the progeny grew to form a sufficiently large tumor to cause the appearance of 
hypoxic regions and consequent reversion by many of the tumor cells to purely glycolytic 
mode of glucose metabolism, then, once the immune cells eventually clear the aerobic 
cells on the outer rim of the tumor, they will encounter competition for glucose from 
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glycolytic cancer cells. Successful acquisition of the common glucose, made possible by 
up-regulation of nutrient transporters of glycolytic cancer cells while in the hypoxic 
regions of the tumor, could cause incapacitation of CTLs due to starvation, thereby 
allowing for continued unrestrained tumor growth (see Figure 1). Within this construct 
one would also expect CSCs to be found primarily in hypoxic regions of the tumors, 
where they would be most protected from the immune response. 
 In order to evaluate the proposed hypothesis,.an agent-based model was created, 
focusing  on interactions between CSCs, aerobic and glycolytic non-CSCs with varying 
glucose demands, , and motile cytotoxic immune cells, whose functionality is nutrient 
dependent. Simulations were run for 1000 time steps, for various initial states of the 
immune system of the host, from complete immunodeficiency to extremely strong 
immune response. Tumor composition was then evaluated for all of the initial immune 
states. 
The proportion of glycolytic non-CSCs increased dramatically with increased 
immune response (Figure 2), supporting the initial hypothesis. Moreover, the proportion 
of CSCs was largest not for the strongest or weakest states of the immune response but 
for intermediate ones (Figure 3), supposedly because in this case the tumor can grow 
large enough to create hypoxic regions but it small enough that the non-stem progeny do 
not outcompete CSCs.  
Next, we hypothesized that if each cell had an individual threshold of sensitivity to 
oxygen, which would determine oxygen-based threshold for a “glycolytic switch”, then 
over time selection towards cells with lower threshold could be observed. However, 
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while the threshold of sensitivity to oxygen ω did change slightly over time, the changes 
both in tumor composition, as well as in the mean values of ω for all three cell types was 
not statistically significant (Figures 8 and 9), suggesting that oxygen availability is less of 
a crucial determinant of the outcome of tumor progression compared to glucose.  
It is of course not possible to claim that competition for common nutrients is the sole 
mechanism whereby CSCs can avoid recognition by the immune system. Instead, we 
propose that competition for resources can provide an additional mechanism whereby 
CTLs are incapacitated, contributing to immune evasion. Noticeably, modifying the 
model to increase or decrease the actual costs of motility and cytotoxicity of CTLs does 
not affect the predicted pattern of behavior (data not reported). Similarly, modification of 
the level of possible infiltration of the tumor by CTLs based on crowding effects did not 
result in qualitative changes in dynamics (data not reported). This can be explained by the 
fact that even when CTLs are physically able to infiltrate the simulated tumor, they are 
quickly starved by glycolytic tumor cells in the hypoxic tumor core, thus achieving the 
same qualitative effects as artificially imposed restrictions on CTL infiltration.  
The predicted pattern dynamics were robust to changes in all parameters evaluated 
with the exception of sensitivity of CSCs to CTLs. Decreasing the probability of cell kill 
for CSCs upon encounter with CTLs by 50% compared to non-CSCs resulted in a similar 
pattern with respect to changes in tumor composition over time for various i0 (Figure 4) 
but the prediction about proportions of CSC:non-CSC at t=1000 was not preserved 
(Figure 5). Literature about sensitivity of CSCs to CTLs is inconclusive: while a number 
of authors report lower sensitivity of CSCs to being recognized by CTLs compared to 
non-CSCs (21, 22), it is unclear whether this is solely an intrinsic property of CSCs, such 
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as lower expression of MHC-II molecules (22), or a by-product of the ‘shielding’ effect 
of non-CSCs. Other groups report efficient recognition of CSCs by CTLs (23), which 
suggests that this is a question that in fact pends further investigation. 
One possible way to understand the interactions of CSCs with their environment is 
from the point of view of normal processes that occur during embryogenesis or tissue 
regeneration. Tissue injury often results in locally created hypoxia due to damage to 
blood vessels, which results in local acidosis as the cells downstream from the damaged 
vessels become oxygen deprived. Lower pH appears to create a locally 
immunosuppressive environment (1), which would allow tissues to rebuild themselves. 
Normalized vascularization after tissue regeneration would allow for exposure of adult 
stem cells to immune cells, thus providing an additional regulatory mechanism to 
stop generation of new tissues. Tumors in turn could harness this mechanism, 
continuing to grow through creating a hypoxic environment, inadvertently 
protecting CSCs. This hypothesis will require further investigation. 
Game theory and cancer 
It has become increasingly recognized and accepted that tumor dynamics is governed 
largely by the process of Darwinian selection, where tumor cells experience and respond 
to various selective pressures, such as competition for resources with each other and 
somatic cells, interaction with predators (the immune system), migration (metastases), all 
within the ‘ecosystem’ of the human body (24-31). One of the well-developed analytical 
approaches to understanding evolving populations is evolutionary game theory, which 
has already been partially applied to cancer (33-39). The main premise of this approach is 
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the assumption that individuals, such as cells, operate for immediate optimization of their 
payoff, which in the context of evolutionary game theory is fitness, i.e., survival and the 
number of progeny. Individuals may use different strategies to achieve this goal, and 
understanding of these strategies and their immediate consequences can provide 
understanding about why a system is evolving in a particular direction. 
 In the context of the proposed model, we assume that it is CSCs that want to 
maximize their fitness and produce a maximal number of other CSCs. They can achieve 
this goal using two strategies: symmetric or asymmetric division, yielding either two 
CSCs or one CSC and one non-CSC, respectively. Symmetric division allows yields 
more CSCs immediately. Asymmetric division may allow for survival of the progeny in 
the long term.  
From this point of view, in the absence of the immune response, or if it did not affect 
the growth dynamics CSCs, one would expect eventual CSC enrichment, as is predicted 
by a number of previously published theoretical models(40, 41), since it is symmetric 
division that would allow CSCs to maximize their fitness. However, in the presence of 
the immune response, the ‘optimal strategy’ becomes mixed, since in order to maximize 
their fitness CSCs now have to divide asymmetrically to protect themselves from the 
immune cells, and the position of the ‘equilibrium strategy’, i.e., the number of times the 
CSC would need to divide symmetrically or asymmetrically in order to maximize its 
fitness, would be different depending on the initial state of the immune response. 
Perhaps, manipulating the tumor microenvironment in such a way as to select for the 
increased asymmetric CSC division could be a potentially fruitful strategy to make the 
tumor more vulnerable to anti-cancer therapies. 
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Therapeutic implications 
Cancer stem cells are hypothesized to be the driving force behind unrestrained tumor 
growth, as they are also resistant to a number of cytotoxic therapies (13; 42-45). One 
possible way to circumvent this problem could involve taking advantage of the immune 
cells, which might be able to eliminate CSCs, even if less efficiently compared to non-
CSCs (23,46-48). However, if the proposed construct is correct, CTLs are unable to do so 
because of the ‘shield’ of differentiated tumor cells that restricts their access to CSCs. 
Therefore, the optimal therapeutic strategy in this case would be not the one to cause the 
most extensive cell mortality but the one that will facilitate the access of cytotoxic 
immune cells to CSCs.  
Two main considerations CSCs and CTLs need to be taken into account. Firstly, both 
theoretical considerations, outlined here, and experimental evidence suggest that CSCs 
are to be primarily found in the hypoxic areas of the tumor (49, 50), where they are the 
most ‘protected’ from the immune cells. Secondly, extensive cytotoxic therapies are 
highly damaging to the immune cells themselves (51), and consequently gained access 
the tumor core and the CSCs would be ineffective if there remain no immune cells that 
could then attack the CSCs. 
The three major approaches that can be taken in chemotherapy administration are 
MTD (maximum tolerated dose), metronomic, and continuous therapy, which is a 
particular case of the metronomic therapy.  
As the name suggests, MTD involves administering the highest possible dose of 
cytotoxic drugs that a patient can tolerate, with the intention of damaging a maximal 
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number of cells and expectation that normal tissues would be able to recover better than 
cancerous ones. The major drawback of MTD from the point of view of the 
considerations, outlined above, is the damage that it causes to the immune cells (51). 
Therefore, even if this could be a good way to reach the CSCs, it is very likely that the 
time it would take for the anti-tumor immune cells to recover would be greater than the 
time it would take for the CSCs to form another ‘shield’. Noticeably, these predictions 
should hold as long as CSCs can be recognized by CTLs. 
Continuous therapy involves administering very low doses of chemotherapy on a 
daily basis, ensuring constant presence of the cytotoxic drug in the patient’s body. While 
this approach is much less toxic to the patient, it still has a problem of giving no time for 
the anti-tumor immune cells to recover, since they would be constantly eliminated by 
continuous inflow of cytotoxic chemical agents. 
Metronomic therapy provides an intermediate case between MTD and continuous 
therapy, and involves administering lower doses of chemotherapy at more frequent 
intervals, but not on a daily basis. This approach could ensure continual ‘peeling off’ of 
the outer layers of the tumor, which protect the CSCs, thus giving anti-tumor immune 
cells access to the tumor core, while allowing sufficient time for CTLs to recover from 
the damaging effects of the therapy and attack the CSCs, thereby giving the best chance 
for more successful long-term tumor elimination. 
Conclusions 
Limited success of some therapies may be rooted not in the lack of effectiveness of the 
cytotoxic drugs themselves but in the lack of understanding of tumor topology. If the 
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differentiated non-CSC cells do indeed provide a barrier to both chemotherapeutic agents 
and the body’s natural defenses, then the problem of halting cancer progression might be 
overcome with appropriate mode of therapy administration. Specifically, if therapy-
resistant CSCs do shield themselves from anti-tumor immune cells by ‘hiding’ in the 
tumor’s hypoxic regions, then slowly exposing these areas using moderate but relatively 
frequently administered levels of chemotherapy might give a better chance for cytotoxic 
lymphocytes to eliminate the tumor. 
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